Moderna to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020Business Wire • 10/15/20
Moderna Wins Permission to Submit Coronavirus Vaccine Candidate for Fast-Track Approval in EuropeThe Motley Fool • 10/15/20
Covid Report: Moderna Gets Key Ruling In Europe; Vaxart Tablet Passes 'Hamster Challenge'Investors Business Daily • 10/14/20
There are seven coronavirus vaccine candidates being tested in the U.S. — here’s where they standMarket Watch • 10/14/20
Moderna Receives Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19 (mRNA-1273)Business Wire • 10/14/20
Here Are the Only 2 Coronavirus Vaccines That Could Meet the FDA's Authorization Guidelines by Year-EndThe Motley Fool • 10/14/20
Moderna's Coronavirus Vaccine Candidate Advances to Regulatory Review in CanadaThe Motley Fool • 10/13/20
Moderna Analyst On Why Coronavirus Vaccine Developer's Stock Is Long-Term AttractiveBenzinga • 10/13/20
Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)Business Wire • 10/13/20
Moderna Doesn't Plan to Enforce Coronavirus Vaccine Patents During PandemicThe Motley Fool • 10/08/20
DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and TherapeuticsBusiness Wire • 10/08/20
Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine ProgramBusiness Wire • 10/08/20